Financial capital joins hands with AI: OSHIDORI (00622) and Terminus open a new chapter in strategic cooperation.
OSHIDORI (00622) announced that it will issue 1.18 billion new shares to Nova Scope Ventures Limited at HK$2.70 per share, for a consideration of approximately HK$3.186 billion, thereby bringing in AI strategic shareholder Terminus.
OSHIDORI (00622) announced that it will issue 1.18 billion new shares to Nova Scope Ventures Limited at HK$2.70 per share, with a consideration of approximately HK$3.186 billion, thereby introducing AI strategic shareholder Terminus. After the transaction is completed, Nova Scope Ventures Limited will hold 14.53% of OSHIDORI's shares, and Wai Wah Tat will indirectly hold approximately 49.60% of Terminus's subsidiary Terminus Shanghai (referred to as the China Operating Company). The China Operating Company, as a joint venture platform between the two parties, has a registered capital of RMB 3.4 billion. This transaction is classified as a long-term major investment by OSHIDORI and represents a strategic opportunity for it to quickly enter the AI industry. The two parties will rely on their respective industrial and technological advantages to achieve deep strategic synergy and deepen their AI industry layout.
The combination of the two parties has solid fundamental support. After the transaction is completed, Wai Wah Tat's net asset scale is expected to further increase to approximately HK$7.51 billion, with capital strength and industrial footprint rising simultaneously. As of the previous trading day, OSHIDORI's market value had reached HK$20.9 billion. A solid financial foundation and strong capital strength provide ample room for the two parties' continued investment and cooperation in the AI field.
For OSHIDORI, this is a ticket to the AI track. Using AI to optimize AI, it breaks through the "stack supplementation" challenge of domestic computing power. With an AI intelligent optimization engine and Agent cluster scheduling as its foundation, Terminus connects the business loop of "intelligent computing centercomputing power leasingToken factory," providing layered, flexible, and scalable AI productivity solutions. At its core, it enables AI Infra Agent to become an automatic adaptation hub, greatly shortening the chip deployment cycle, increasing hardware utilization, and further enabling agents to achieve autonomous tuning, pushing AI optimization from the operator layer to the full stack and toward a new stage of automatic system optimization. Its self-developed hybrid intelligent computing platform connects the "modelcomputing powerToken" chain, upgrading traditional "manual allocation of computing power" to "reverse customization by models + Agent AI autonomous scheduling of resources, optimizing cache, and reducing manual intervention." Reverse customization of computing cluster configurations based on model requirements, continuously improving Token output per unit of computing power and cluster operating efficiency. Downstream, the company integrates with the domestic computing ecosystem and is compatible with diverse chip architectures; upstream, it enhances Token production capacity through Agents, forming a value loop of AI software-hardware integration. At a time when demand for AI computing power is growing explosively, the scarcity of such assets is self-evident.
For Terminus, this also means that its AI assets, technological strength, and business prospects will gain broader recognition in the capital market. The announcement also makes clear that this is an arrangement focused on long-term mutual growth.
Related Articles
.png)
Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary obtains drug registration certificate for Compound Amino Acid Injection

HK Stock Market Move | LIFETECH SCI (01302) rises over 3%; the Yuranos Plus abdominal aortic stent graft system recently received NMPA approval for marketing

HK Stock Market Move | CTIHK (06055) rose over 4% in late trading; the company showcased multiple new tobacco products at the German tobacco exhibition.
Tianjin Tianyao Pharmaceuticals (600488.SH) subsidiary obtains drug registration certificate for Compound Amino Acid Injection
.png)
HK Stock Market Move | LIFETECH SCI (01302) rises over 3%; the Yuranos Plus abdominal aortic stent graft system recently received NMPA approval for marketing

HK Stock Market Move | CTIHK (06055) rose over 4% in late trading; the company showcased multiple new tobacco products at the German tobacco exhibition.

RECOMMEND





